

# Matthew F Pullen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4619217/publications.pdf>

Version: 2024-02-01

14  
papers

2,000  
citations

1170033

9  
h-index

1336881

12  
g-index

17  
all docs

17  
docs citations

17  
times ranked

5291  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2021, 72, e835-e843.	2.9	103
2	Lessons Learned From Conducting Internet-Based Randomized Clinical Trials During a Global Pandemic. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa602.	0.4	9
3	Change in Plasma Cryptococcal Antigen Titer Is Not Associated With Survival Among Human Immunodeficiency Virus–infected Persons Receiving Preemptive Therapy for Asymptomatic Cryptococcal Antigenemia. <i>Clinical Infectious Diseases</i> , 2020, 70, 353-355.	2.9	3
4	Cerebrospinal Fluid Early Fungicidal Activity as a Surrogate Endpoint for Cryptococcal Meningitis Survival in Clinical Trials. <i>Clinical Infectious Diseases</i> , 2020, 71, e45-e49.	2.9	17
5	Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa500.	0.4	38
6	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. <i>Annals of Internal Medicine</i> , 2020, 173, 623-631.	2.0	444
7	Symptoms of COVID-19 Outpatients in the United States. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa271.	0.4	38
8	Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. <i>Canadian Journal of Anaesthesia</i> , 2020, 67, 1201-1211.	0.7	19
9	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 517-525.	13.9	1,081
10	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa130.	0.4	160
11	Tuberculosis at the animal–human interface in the Ugandan cattle corridor using a third-generation sequencing platform: a cross-sectional analysis study. <i>BMJ Open</i> , 2019, 9, e024221.	0.8	3
12	Protective Immunogenicity of Group A Streptococcal M-Related Proteins. <i>Vaccine Journal</i> , 2015, 22, 344-350.	3.2	18
13	Genetic Dissection of the <i>Gpnmb</i> Network in the Eye. , 2011, 52, 4132.		30
14	Feasibility of SARS-CoV-2 Antibody Testing in Remote Outpatient Trials. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	0